摘要
目的回顾性研究正常对照人群及弥漫性毒性甲状腺肿(Graves病)患者治疗前后的甲状腺激素水平及其与血清胱抑素C水平的关系。方法选择2013年1月至2015年9月于本院就诊的Graves病患者共185例,另选取甲状腺功能正常者24例为对照组,所有患者均行甲状腺功能(FT_3、FT_4、TSH)及胱抑素C(CysC)检测,并筛选其中检测后接受了碘-131治疗的患者19例,在其治疗后再次检测甲状腺功能(FT_3、FT_4、TSH)及胱抑素C(CysC),对比并分析结果。结果Graves病组患者胱抑素C水平明显高于对照组水平(P<0.05);Graves病组患者甲状腺激素水平与胱抑素C检测结果呈正相关,FT_3、FT_4与胱抑素C的相关系数分别为r_s=0.69和r_s=0.66(均P<0.05);Graves病患者治疗后其甲状腺激素水平与胱抑素C水平均较治疗前显著下降,两组差异具有统计学意义,治疗后与对照组比较,差异无统计学意义。结论Graves病是胱抑素C升高的重要原因;Graves病患者治疗前后胱抑素C水平与甲状腺激素水平水平呈正相关,提示在排除肾脏疾病的前提下,胱抑素C可反映甲状腺功能状态。
Objective To analyze the relationship and the factors between the thyroid function in Graves＇ disease and the cystatin C （CysC） levels and observe their correlation of different levels and treatments. Methods 185 patients with Graves hyperthyroidism who receiving treatment from January 2013 to September 2015 at Xijing Hospital Department of Nuclear Medicine and 24 healthy patients were recruited. Their serum level of thyroid hormone （FT3 ,FT4 ,TSH） and CysC were detected and compared. 19 in the 185 patients＇ were detected again after Iodine-131 treatment. Results Serum CysC concentration in the Graves＇ Disease group was significantly higher than the normal group, and it was positively correlated with the serum concentrations of FT3 （ rs = 0.69, P 〈 0.01 ） and FT4 （ rs = 0.66, P 〈 0.05 ）. After treatment, the CysC level decreased with thyroid hormones. The difference was statistically significant （ P 〈 0.05 ）. Conclusion Graves＇ Disease hyperthyroidism is one of the important reasons for the increasing of cystatin C. Serum CysC concentration was positively correlated with the severity of thyroid dysfunction before and after the treatments in patients with Graves＇ Disease, which indicates CysC can reflect the thyroid function status when kidney disease was excluded.
出处
《标记免疫分析与临床》
CAS
2017年第5期490-494,共5页
Labeled Immunoassays and Clinical Medicine
